kr567.50
2.16%
Copenhagen, Oct 07, 04:59 pm CEST. Closed.
ISIN
DK0060055861
Symbol
CHEMM

ChemoMetec Target price 2026 - Analyst rating & recommendation

ChemoMetec Classifications & Recommendation

Buy
91%
Hold
9%

ChemoMetec Price Target

Target Price kr617.10
Price kr567.50
Potential
Number of Estimates 7
7 Analysts have issued a price target ChemoMetec 2027 . The average ChemoMetec target price is kr617.10. This is higher than the current stock price. The highest price target is , the lowest is .
A rating was issued by 11 analysts: 10 Analysts recommend ChemoMetec to buy, 1 to hold and 0 to sell.
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
Analyst Estimates: Analysts believe that the ChemoMetec stock has an average upside potential 2027 of . Most analysts recommend the ChemoMetec stock at Purchase.

Sales and Margin forecast 2027, 2028 to 2033

Create a premium account to unlock analyst estimates. Learn more

Select at least one metric to display the chart.


Jun '26 2027
Estimates
Revenue Million kr 511.06 599.98
3.13% 17.40%
EBITDA Margin 55.03% 53.96%
1.07% 1.95%
Net Margin 39.49% 39.09%
12.03% 1.02%

5 Analysts have issued a sales forecast ChemoMetec 2027 . The average ChemoMetec sales estimate is

kr600m
unlock
. This is
17.40% higher
unlock
than the revenue of the last 12 months(TTM). The highest sales forecast is
kr615m 20.40%
unlock
, the lowest is
kr567m 11.03%
unlock
.

This results in the following potential growth metrics:

Revenue Estimates

2026 kr511m 3.13%
2027
kr600m 17.40%
unlock
2028
kr712m 18.63%
unlock
2029
kr772m 8.46%
unlock
2030
kr902m 16.87%
unlock
2031
kr1.3b 46.76%
unlock
2032
kr1.5b 12.84%
unlock
2033
kr1.7b 11.51%
unlock

6 Analysts have issued an ChemoMetec EBITDA forecast 2027. The average ChemoMetec EBITDA estimate is

kr324m
unlock
. This is
15.11% higher
unlock
than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is
kr332m 17.97%
unlock
, the lowest is
kr307m 9.06%
unlock
.

This results in the following potential growth metrics and future EBITDA Margins:

EBITDA Estimates

2026 kr281m 4.22%
2027
kr324m 15.11%
unlock
2028
kr404m 24.71%
unlock
2029
kr458m 13.52%
unlock
2030
kr523m 14.11%
unlock
2031
kr833m 59.32%
unlock
2032
kr939m 12.73%
unlock
2033
kr1.0b 11.56%
unlock

EBITDA Margin

2026 55.03% 1.07%
2027
53.96% 1.95%
unlock
2028
56.73% 5.13%
unlock
2029
59.38% 4.67%
unlock
2030
57.97% 2.37%
unlock
2031
62.94% 8.57%
unlock
2032
62.88% 0.10%
unlock
2033
62.91% 0.05%
unlock

6 ChemoMetec Analysts have issued a net profit forecast 2027. The average ChemoMetec net profit estimate is

kr235m
unlock
. This is
16.21% higher
unlock
than the net profit for the last 12 months(TTM). The highest net profit forecast is
kr243m 20.60%
unlock
, the lowest is
kr218m 8.02%
unlock
.

This results in the following potential growth metrics and future Net Margins:

Net Profit Estimates

2026 kr202m 15.54%
2027
kr235m 16.21%
unlock
2028
kr294m 25.42%
unlock
2029
kr340m 15.69%
unlock

Net Margin

2026 39.49% 12.03%
2027
39.09% 1.02%
unlock
2028
41.33% 5.73%
unlock
2029
44.09% 6.68%
unlock

Earnings per share, P/E ratio and EV/sales Estimates 2027, 2028 to 2033

Create a premium account to unlock analyst estimates. Learn more

Select at least one metric to display the chart.


Jun '26 2027
Estimates
Earnings Per Share kr 11.60 13.56
15.54% 16.90%
P/E 42.78
EV/Sales 16.49

6 Analysts have issued a ChemoMetec forecast for earnings per share. The average ChemoMetec EPS is

kr13.56
unlock
. This is
16.90% higher
unlock
than earnings per share in the financial year 2026. The highest EPS forecast is
kr14.07 21.29%
unlock
, the lowest is
kr12.60 8.62%
unlock
.

This results in the following potential growth metrics and future valuations:

Earnings Per Share

2026 kr11.60 15.54%
2027
kr13.56 16.90%
unlock
2028
kr17.01 25.44%
unlock
2029
kr19.67 15.64%
unlock
2030
kr32.06 62.99%
unlock

P/E ratio

Current 50.00 21.02%
2027
42.78 14.44%
unlock
2028
34.11 20.27%
unlock
2029
29.48 13.57%
unlock

Based on analysts' sales estimates for 2027, the ChemoMetec stock is valued at an EV/Sales of

16.49
unlock
and an P/S ratio of
16.97
unlock
.

This results in the following potential growth metrics and future valuations:

EV/Sales

Current 19.35 13.19%
2027
16.49 14.80%
unlock
2028
13.90 15.70%
unlock
2029
12.81 7.80%
unlock
2030
10.96 14.43%
unlock
2031
7.47 31.86%
unlock
2032
6.62 11.38%
unlock
2033
5.94 10.32%
unlock

P/S ratio

Current 19.92 13.26%
2027
16.97 14.82%
unlock
2028
14.30 15.70%
unlock
2029
13.19 7.80%
unlock
2030
11.28 14.44%
unlock
2031
7.69 31.86%
unlock
2032
6.81 11.38%
unlock
2033
6.11 10.32%
unlock

Current ChemoMetec Upgrades & Downgrades

Create a Premium account to unlock Upgrades/Downgrades. Learn more
Analyst Rating Action Date
BERENBERG
Locked
➜
Locked
Locked Sep 21 2026
DNB CARNEGIE
Locked
➜
Locked
Locked Sep 17 2026
BERENBERG
Locked
➜
Locked
Locked May 18 2026
BERENBERG
Locked
➜
Locked
Locked May 17 2026
DNB CARNEGIE
Locked
➜
Locked
Locked May 08 2026
DNB CARNEGIE
Locked
➜
Locked
Locked May 07 2026
BERENBERG
Locked
➜
Locked
Locked Feb 23 2026
Analyst Rating Date
Locked
BERENBERG:
Locked
➜
Locked
Sep 21 2026
Locked
DNB CARNEGIE:
Locked
➜
Locked
Sep 17 2026
Locked
BERENBERG:
Locked
➜
Locked
May 18 2026
Locked
BERENBERG:
Locked
➜
Locked
May 17 2026
Locked
DNB CARNEGIE:
Locked
➜
Locked
May 08 2026
Locked
DNB CARNEGIE:
Locked
➜
Locked
May 07 2026
Locked
BERENBERG:
Locked
➜
Locked
Feb 23 2026

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today